Target Audience
Investors and physicians and scientists in academia, industry (including emerging biotech companies), and regulatory agencies who have an interest in the strategic, preclinical, clinical and regulatory aspects of efficient IO drug development.
This program will also support those who are beginning careers in IO drug development.